These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36450107)

  • 1. A Multicenter, Randomized, Double-Blind Evaluation of the Efficacy of TJO-087 Versus 0.05% Cyclosporine A in Moderate to Severe Dry Eye.
    Eom Y; Yoon KC; Kim HK; Song JS; Hyon JY; Kim HM
    J Ocul Pharmacol Ther; 2023; 39(1):27-35. PubMed ID: 36450107
    [No Abstract]   [Full Text] [Related]  

  • 2. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
    Sall K; Stevenson OD; Mundorf TK; Reis BL
    Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
    Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial.
    Park CH; Lee HK; Kim MK; Kim EC; Kim JY; Kim TI; Kim HK; Song JS; Yoon KC; Lee DH; Chung TY; Choi CY; Kim HS
    BMC Ophthalmol; 2019 Jun; 19(1):131. PubMed ID: 31208393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
    Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
    Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, Safety, and Tolerability of a Novel Cyclosporine, a Formulation for Dry Eye Disease: A Multicenter Phase II Clinical Study.
    Peng WY; Chen RX; Dai H; Zhu L; Li Y; Gao ZQ; Li XY; Zhou SY
    Clin Ther; 2021 Mar; 43(3):613-628. PubMed ID: 33546885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
    Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
    Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploration of efficacy and mechanism of 0.05% cyclosporine eye drops (II) monotherapy in allergic conjunctivitis-associated dry eye.
    Jiao X; Qi Y; Gao N; Zhang C; Zhao S; Yang R
    Eye (Lond); 2024 Apr; 38(5):937-944. PubMed ID: 37904000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial.
    Akpek EK; Wirta DL; Downing JE; Tauber J; Sheppard JD; Ciolino JB; Meides AS; Krösser S
    JAMA Ophthalmol; 2023 May; 141(5):459-466. PubMed ID: 37022717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a 0.05% cyclosporine a topical nanoemulsion in dry eyes with obstructive meibomian gland dysfunction.
    Rhim JW; Eom Y; Yoon EG; Park SY; Choi Y; Song JS; Kim HM
    Jpn J Ophthalmol; 2022 May; 66(3):254-263. PubMed ID: 35233694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of 0.05% cyclosporine A combined with vitamin A palmitate in the treatment of meibomian gland dysfunction-related dry eye].
    Hao YR; Li SY; Bao JY; Wang JY; Li A; Tian L; Jie Y
    Zhonghua Yan Ke Za Zhi; 2024 Feb; 60(2):127-136. PubMed ID: 38296318
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye.
    Park CH; Kim MK; Kim EC; Kim JY; Kim TI; Kim HK; Song JS; Yoon KC; Lee DH; Lee HK; Chung TY; Choi CY; Kim HS
    Korean J Ophthalmol; 2019 Aug; 33(4):343-352. PubMed ID: 31389210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
    Baudouin C; de la Maza MS; Amrane M; Garrigue JS; Ismail D; Figueiredo FC; Leonardi A
    Eur J Ophthalmol; 2017 Nov; 27(6):678-685. PubMed ID: 28708219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye.
    Sall KN; Cohen SM; Christensen MT; Stein JM
    Eye Contact Lens; 2006 Jan; 32(1):21-6. PubMed ID: 16415689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.
    Stevenson D; Tauber J; Reis BL
    Ophthalmology; 2000 May; 107(5):967-74. PubMed ID: 10811092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Topical 0.05% Cyclosporine A Eye Drops on Post-Femtosecond-Assisted Laser In Situ Keratomileusis Ocular Surface Recovery: A Randomized Clinical Trial.
    Zhao L; Duan H; Ma B; Yang T; Zhou Y; Liu Y; Chen J; Chen Y; Qi H
    Eye Contact Lens; 2024 Aug; 50(8):348-356. PubMed ID: 38865592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety, and acceptability of a lipid-based artificial tear formulation: a randomized, controlled, multicenter clinical trial.
    Simmons PA; Carlisle-Wilcox C; Chen R; Liu H; Vehige JG
    Clin Ther; 2015 Apr; 37(4):858-68. PubMed ID: 25659956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Topical Cyclosporine-A or Topical Chloroquine on Post-LASIK Ocular Surface Stability - A Randomized Controlled Trial.
    Titiyal JS; Goswami A; Kaur M; Sharma N; Maharana PK; Velpandian T; Pandey RM
    Curr Eye Res; 2023 Jun; 48(6):557-563. PubMed ID: 36800492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
    Toker E; Asfuroğlu E
    Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye.
    Park Y; Song JS; Choi CY; Yoon KC; Lee HK; Kim HS
    J Ocul Pharmacol Ther; 2017 Mar; 33(2):66-72. PubMed ID: 27929721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.